Baseline predictors of ninety percent or higher antiretroviral therapy adherence in a diverse urban sample: The role of patient autonomy and fatalistic religious beliefs

AIDS Patient Care and STDs

Volumn 25, Issue 2, 2011, Pages 103-111

  Finocchario Kessler, S ^a   Catley, D ^a   Berkley Patton, J ^a   Gerkovich, M ^a   Williams, K ^a   Banderas, J ^a   Goggin, K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; BRIEF MOTIVATION SCALE; DRUG MONITORING; ELECTRONICS; FAMILY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MOTIVATION; OUTCOME ASSESSMENT; PATIENT AUTONOMY; PATIENT COMPLIANCE; PREDICTOR VARIABLE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELIGION; SUPPORT GROUP;

ADULT; ANTI-HIV AGENTS; DRUG MONITORING; FEMALE; HIV INFECTIONS; HUMANS; INTERVIEWS AS TOPIC; MALE; MOTIVATION; PATIENT COMPLIANCE; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; RELIGION; SELF EFFICACY; URBAN POPULATION;

EID: 79551678763     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2010.0319     Document Type: Article

References (62)

1. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006;43:939-941.
2. Robbins G, Johnson K, Chang Y, et al. Predicting Virologic Failure in an HIV Clinic. Clin Infect Dis 2010:50:779-786.
3. Gardner EM, Sharma S, Peng G, et al. Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS 2008;22:75-82.
4. Vernazza P, Hirschel B, Bernasconi E, Flepp M. HIV transmission under highly active antiretroviral therapy. Lancet 2008;372:1806-1807.
5. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: Systematic review and meta-analysis. AIDS 2009;23:1397-1404.
6. Valenti W. Treatment adherence improves outcomes and manages costs. AIDS Read 2001;11:77-80.
7. Proctor VE, Tesfa A, Tompkins DC. Barriers to adherence to highly active antiretroviral therapy as expressed by people living with HIV-AIDS. AIDS Patient Care STDs 1999;13:535-544.
8. Howard AA, Arnsten JH, Lo Y, et al. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS 2002;16:2175-2182.
9. Arnsten JH, Li X, Mizuno Y, et al. Factors associated with antiretroviral therapy adherence and medication errors among HIV-infected injection drug users. J Acquir Immune Defic Syndr 2007;46(Suppl 2):S64-71.
10. Ickovics J, Meade C. Adherence to HAART among patients with HIV: Breakthroughs and barriers. AIDS Care 2002;14: 309-318.
11. Vyavaharkar M, Moneyham L, Tavakoli A, et al. Social support, coping, and medication adherence among HIVpositive women with depression living in rural areas of the southeastern United States. AIDS Patient Care STDs 2007;21:667-680.
12. Lucas GM, Mullen BA, McCaul ME, Weidle PJ, Hader S, Moore RD. Adherence, drug use, and treatment failure in a methadone-clinic-based program of directly administered antiretroviral therapy. AIDS Patient Care STDs 2007;21: 564-574.
13. Lazo M, Gange SJ, Wilson TE, et al. Patterns and predictors of changes in adherence to highly active antiretroviral therapy: Longitudinal study of men and women. Clin Infect Dis 2007;45:1377-1385.
14. Dasinger L, Speiglman R. Homelessness prevention: The effect of a shallow rent subsidy program on housing outcomes among people with HIV or AIDS. AIDS Behav 2007;11:S128-S139.
15. Schwarcz S, Hsu1 L, Vittinghoff E, Vu A, Bamberger J, Katz M. Impact of housing on the survival of persons with AIDS.BMC Public Health 2009;9:220.
16. Shah B, Walshe L, Saple DG, et al. Adherence to antiretroviral therapy and virologic suppression among HIVinfected persons receiving care in private clinics in Mumbai, India. Clin Infect Dis 2007;44:1235-1244.
17. Nilsson Schonnesson L, Williams ML, Ross MW, Bratt G, Keel B. Factors associated with suboptimal antiretroviral therapy adherence to dose, schedule, and dietary instructions. AIDS Behav 2007;11:175-183.
18. Molassiotis A, Nahas-Lopez V, Chung WY, Lam SW, Li CK, Lau TF. Factors associated with adherence to antiretroviral medication in HIV-infected patients. Int J STD AIDS 2002;13:301-310.
19. Kremer H, Ironson G, Porr M. Spiritual and mind-body beliefs as barriers and motivators to HIV-treatment decisionmaking and medication adherence? A qualitative study. AIDS Patient Care STDs 2009:23:127-134.
20. Parsons SK, Cruise PL, Davenport WM, Jones V. Religious beliefs, practices and treatment adherence among individuals with HIV in the southern United States. AIDS Patient Care STDs 2006;20:97-111.
21. Wallston K, Malcarne V, Flores L, et al. Does God determine your health? The God locus of health control scale. Cogn Ther Res 1999:33:131-142.
22. Kinney AY, Emery G, Dudley WN, Croyle RT. Screening behaviors among African American women at high risk for breast cancer: Do beliefs about god matter? Oncol Nurs Forum 2002;29:835-843.
23. Kennedy S, Goggin K, Nollen N. Adherence to HIV medications: Utility of the theory of self-determination. Cogn Ther Res 2004;28:611-628.
24. Park J, Nachman S. The link between religion and HAART adherence in pediatric HIV patients. AIDS Care 2010;15: 1-6.
25. Lynam I, Catley D, Goggin K, et al. Autonomous regulation and locus of control as predictors of antiretroviral medication adherence. J Health Psychol 2009;14:578-586.
26. Williams GC, Frankel RM, Campbell TL, Deci EL. Research on relationship-centered care and healthcare outcomes from the Rochester Biopsychosocial Program: A Self-Determination Theory integration. Fam Sys Health 2000;18:79-90.
27. Williams GC, Rodin GC, Ryan RM, Grolnick WS. Autonomous regulation and long-term medication adherence in adult outpatients. Health Psychol 1998;17:269-276.
28. Williams GC, Gagne M, Ryan RM, Deci EL. Facilitating autonomous motivation for smoking cessation. Health Psychol 2002;21:40-50.
29. Williams GC, Freedman ZR, Deci EL. Supporting autonomy to motivate glucose control in patients with diabetes. Diabetes Care 1998;21:1644-1651.
30. Ryan RM. & Deci EL. Self-determination theory and the facilitation of intrinsic motivation, social development, and well-being. Am Psychol 2000;55:68-78.
31. Goggin K, Williams K, Gerkovich M, Outcomes of Project MOTIV8: A RCT of novel behavioral interventions for ART adherence [Abstract 62097]. Presented at International Association of Physicians in AIDS Care Conference, 2010.
32. Remien RH, Stirratt MJ, Dolezal C, et al. Couple-focused support to improve HIV medication adherence: A randomized controlled trial. AIDS 2005;19:807-814.
33. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-na've cohort initiating triple antiretroviral therapy. J Infect Dis 2005;191:339-347.
34. Radloff LS. The CES-D scale: A self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.
35. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Beh 1983;24:385-396.
36. Wagner GJ, Kanouse DE, Koegel P, Sullivan G. Correlates of HIV antiretroviral adherence in persons with serious mental illness. AIDS Care 2004;16:501-506.
37. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999;14:1-24.
38. Bakken S, Holzemer WL, Brown MA, et al. Relationships between perception of engagement with health care provider and demographic characteristics, health status, and adherence to therapeutic regimen in persons with HIV/ AIDS. AIDS Patient Care and STDs 2000;14:189-197.
39. Johnson M, Neilands T, Dilworth S, Morin S, Remien R, Chesney M. The role of self-efficacy in HIV treatment adherence: Validation of the HIV Treatment Adherence Self- Efficacy Scale (HIV-ASES). J Behav Med 2007;30:359-357.
40. Simoni JM, Frick PA, Lockhart D, & Liebovitz D. Mediators of social support and antiretroviral adherence among an indigent population in New York city. AIDS Patient CARE STDs 2002;16:431-439.
41. Prochaska JO, Velicer WF. The Transtheoretical Model of health behavior change. Am J Health Promot 1997;12: 38-48.
42. Catley D, Gerkovich M, Williams K, Goggin K. A 4-item measure of motivation to adhere that predicts MEMS adherence over 48 weeks [Abstract 62095]. Presented at International Association of Physicians in AIDS Care Conference 2010.
43. Amrhein PC, Miller WR, Yahne CE, Palmer M, Fulcher L. Client commitment language during motivational interviewing predicts drug use outcomes. J Consult Clin Psychol 2003;71:862-878.
44. Williams GC, Grow VM, Freedman Z, Ryan RM, Deci EL. Motivational predictors of weight loss and weight-loss maintenance. J Pers Soc Psychol 1996;70:115-126.
45. Wallston KA, Wallston BS, DeVellis R. Development of the Multidimensional Health Locus of Control (MHLC) scales. Health Educ Monogr 1978;6:160-170.
46. Carver C. You want to measure coping but your protocol's too long: Consider the Brief COPE. Int J Behav Med 1997;4: 92-100.
47. Pargament K, Koenig H, Perez I. The many methods of religious coping: Development and internal validation of the RCOPE. J Clin Psychol 2000;56:519-543.
48. Connors GJ, Tonigan JS, Miller WR. A measure of religious background and behavior for use in behavior change research. Psych Addict Behav 1996;10:90-96.
49. Florez K, Aguirre A, Viladrich A, Cespedes A, De La Cruz A, Abraido-Lanza A. Fatalism or destiny? A qualitative study and interpretative framework on dominican women's breast cancer beliefs. J Immigrant Minority Health 2009;11:291-301.
50. Crute S. African-American and Latina women fight culture to obtain care. J Int Assoc Physicians AIDS Care 1998;1:3.
51. Pargament K, McCarthy S, Shah P, et al. Religion and HIV: A review of the literature and clinical implications. South Med J 2004;97:1201-1209.
52. Bosworth HB. The importance of spirituality/religion and health-related quality of life among individuals with HIV/ AIDS. J Gen Intern Med 2006;21(Suppl 5):S3-4.
53. Dalmida S, Holstad M, DiIorio C, Laderman G. Spiritual well-being, depressive symptoms, and immune status among women living with HIV/AIDS. Women Health 2009;49:119-143.
54. Ironson G, Kremer H. Spiritual transformation, psychological well-being, health, and survival in people with HIV. Int J Psychiatry Med 2009;39:263-281.
55. Ironson G, Stuetzle R, Fletcher MA. An increase in religiousness/ spirituality occurs after HIV diagnosis and predicts slower disease progression over 4 years in people with HIV. J Gen Intern Med 2006;21(Suppl 5):S62-68.
56. Paterson DL, Swindels S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
57. Pew Forum on Religious & Public Life. U.S. Religious Landscape Survey 2008. http://religions.pewforum.org/pdf/report2-religious-landscape-study-full. pdf (Last accessed July 2010).
58. Newlin K, Knafl K, Melkus GD. African-American spirituality: a concept analysis. ANS Adv Nurs Sci 2002;25:57-70.
59. Centers for Disease Control and Prevention. HIV/AIDS Among African Americas. Updated August 2009. www.cdc.gov/hiv/topics/aa/resources/factsheets/ pdf/aa.pdf (Last accessed July 2010).
60. Berkley-Patton J, Bowe-Thompson C, Bradley-Ewing A, et al. Taking it to the Pews: A CBPR-guided HIV awareness and screening project with black churches. AIDS Educ Prev 2010;22:218-237.
61. Atkinson M, Petrozzino J. An evidence-based review of treatment-related determinants of patients' nonadherence to HIV medications. AIDS Patient Care STDs 2009;23:903-914.
62. Simoni J, Amico K, Smith L, Nelson K. Antiretroviral adherence interventions: Translating research findings to the real world clinic. Curr HIV/AIDS Rep 2010;7:44-51.